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Abstract: Human botulism is most commonly caused by botulinum neurotoxin (BoNT) serotypes A,
B, and E. For this work, we sought to develop a human monoclonal antibody (mAb)-based antitoxin
capable of binding and neutralizing multiple subtypes of BoNT/E. Libraries of yeast-displayed
single chain Fv (scFv) antibodies were created from the heavy and light chain variable region
genes of humans immunized with pentavalent-toxoid- and BoNT/E-binding scFv isolated by
Fluorescence-Activated Cell Sorting (FACS). A total of 10 scFv were isolated that bound one or more
BoNT/E subtypes with nanomolar-level equilibrium dissociation constants (KD). By diversifying the
V-regions of the lead mAbs and selecting for cross-reactivity, we generated three scFv that bound all
four BoNT/E subtypes tested at three non-overlapping epitopes. The scFvs were converted to IgG
that had KD values for the different BoNT/E subtypes ranging from 9.7 nM to 2.28 pM. An equimolar
combination of the three mAbs was able to potently neutralize BoNT/E1, BoNT/E3, and BoNT/E4
in a mouse neutralization assay. The mAbs have potential utility as therapeutics and as diagnostics
capable of recognizing multiple BoNT/E subtypes. A derivative of the three-antibody combination
(NTM-1633) is in pre-clinical development with an investigational new drug (IND) application filing
expected in 2018.
Keywords: botulinum neurotoxin; oligoclonal antibodies; serotype E botulism; recombinant
antibodies; antibody engineering; mouse neutralization assay; botulinum antitoxin
Key contribution: We report generation of highly potent antibodies to botulinum serotype E that
bind non-overlapping epitopes, and that provide protection in an animal model of disease. Three of
the antibodies reported here form the basis of an antitoxin for botulism due to serotype E, now in
clinical development.
Toxins 2018, 10, 105; doi:10.3390/toxins10020105 www.mdpi.com/journal/toxins
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1. Introduction
Botulinum type E neurotoxins (BoNT/E) belong to one of at least seven immunologically distinct
groups of neurotoxins (BoNT/A-G and BoNT/HA [1,2]) produced by different species of bacteria
from the genus Clostridium [3,4]. BoNT/E is produced by Clostridium butyricum (subtypes E4 [5,6] and
E5 [7,8]) and Clostridium botulinum (subtypes E1, E2, E3 [9] E6 [10], E7, E8 [11], E9 [12], E10, E11 [13],
and E12 [14]). Within the twelve reported E subtypes, amino acid sequence homology ranges from 99%
(subtypes 1 and 2) to 88–90% (subtype 9 versus all others) [14,15]. All BoNTs have similar secondary
structures consisting of three domains: a binding domain (HC), a translocation domain (HN), and a
zinc metalloprotease domain (LC) [16]. However, the arrangement of the domains in serotype E
toxins is significantly different from other serotypes as identified by electron microscopy [17] and
X-ray crystallography [18] (PDB:3FFZ) with the LC and HC packed against each other rather than in
an extended conformation [19]. BoNTs are produced as a single polypeptide. In order to reach full
catalytic activity, the progenitor BoNT polypeptide is cleaved between the proteolytic domain and
the translocation domain, with the two resulting peptides being linked by a disulfide bridge. Toxins
produced in proteolytic C. botulinum strains are cleaved during processing, but in non-proteolytic
strains, such as those that produce all type E and some type B toxins, trypsinization is used to cleave
the LC-HN and achieve full toxicity [20].
Several soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins
are known to interact and produce pores through which neurotransmitters are released from the nerve
terminals to muscles, provoking muscle twitches. Botulinum neurotoxins act at the presynaptic level
by cleaving one or more of the SNARE complex proteins, inhibiting neurotransmitter release [21],
resulting in the flaccid paralysis that characterizes botulism. Because of its unique structure, BoNT/E
results in the most rapid rate of intoxication of all reported serotypes [18,22].
While the majority of type E cases are foodborne, associated with raw or preserved fish or marine
mammal products [23], rare cases due to other foods have been reported [7,14,24]. In addition, cases
of wound botulism in intravenous drug users [25], infant botulism [5], and adult toxicoinfections
associated with subtype E4, produced in C. butyricum [26] have been reported. Botulism outbreaks
can involve one or several individuals and can be from mild to serious, even fatal, with prolonged
intensive care and mechanical ventilation required [24,25].
The current treatment for adult botulism is heptavalent (serotypes A–G) equine botulism antitoxin
(BAT) [27]. BAT is immunogenic, and hypersensitivity reactions have been reported, including serum
sickness and asystole [27]. BAT is a F(ab’)2 product with short serum half-lives (7.5–34.2 h), which
eliminates its use for the prevention of botulism and limits its effectiveness as a treatment. Relapses
of botulism after treatment have been noted [28]. As an alternative, human monoclonal antibody
(mAb)-based antitoxins composed of three mAbs [29,30] binding non-overlapping epitopes [31] are
being developed. The most advanced of these is for serotype A (NTM-1631, formerly known as XOMA
3AB), which has completed a Phase 1 clinical trial with no serious adverse effects [32].
Here, we report the generation of a panel of high affinity human BoNT/E mAbs using yeast
display and Fluorescence-Activated Cell Sorting (FACS) technologies. mAbs were characterized with
respect to ability to bind four BoNT/E subtypes, BoNT domain bound, and epitope overlap. Epitope
mapping was compared to previously published data using cryo-EM [17] and alanine scanning for four
of the mAbs [33,34]. One of the mAbs was affinity-matured. A combination of three mAbs binding
four BoNT/E subtypes potently neutralized each BoNT/E subtype.
2. Results
2.1. Characterization of Monoclonal Antibodies
Yeast-displayed single chain Fv (scFv) antibody libraries were constructed from the VH and Vk
genes of human volunteers immunized with pentavalent BoNT toxoid (serotypes A, B, C, D, and E).
The construction of these libraries has previously been reported [35,36]. Yeast surface scFv display
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was induced, and the libraries were sorted for three to four rounds using FACS after staining with
BoNT/E3. After sorting, individual colonies were picked, induced, and evaluated for BoNT/E3
binding using flow cytometry. The genes of the scFv showing significant binding to BoNT/E3 were
sequenced, resulting in the identification of 10 unique scFv (Table 1). The KD values of these ten
yeast-displayed scFv were measured versus BoNT/E3 by flow cytometry and ranged between 0.10 and
15.4 nM. These ten scFv were further characterized for their binding to BoNT/E1, /E2, /E3, and /E4
(Table 1). One mAb (3E2) was identified that bound all four subtypes with high affinity (KD < 2 nM).
Two mAbs (4E17 and 3E6) were identified that bound all four subtypes, with KD values ranging from
15 nM to greater than 100 nM. Four mAbs were identified that bound three subtypes (3E4, 3E5, 4E11,
and 4E16).
Seven scFv were converted to IgG consisting of the human gamma 1 constant region (Fcγ1) and
the human kappa or lambda constant region as previously described for subsequent studies [31]. In the
case of 4E17, a higher-affinity version previously described (4E17.1) was chosen for IgG conversion [33].
The KD values of IgG for BoNT/E3 ranged from 7.24 to 0.002 nM. In most cases, improved binding
was seen with KD values that were 1.3- to 75-fold lower than the scFv KD (Table 1). Improvement
in KD values upon scFv to IgG conversion has been previously reported and is partially due to the
stabilization of the VH–Vk interface provided by the constant regions [31,36].
Table 1. Binding properties of BoNT/E yeast-displayed single chain Fv (scFv) and IgG. Equilibrium
binding constants (KD) of yeast-displayed scFv for BoNT/E subtypes 1 through 4 were determined
by flow cytometry. Soluble IgG KD for BoNT/E3 were determined by flow fluorimetry in a KinExA.
The BoNT/E domain bound by each antibody was determined as described in the Methods, and in
Figure 1. 3E6.1, 3E6.2, and 4E17.1 are higher affinity derivatives of 3E6 and 4E17, respectively. 4E17
and 4E17.1 were previously reported [33].
mAb Name Domain Bound
KD (×10−9 M)
BoNT/E1, scFv BoNTE2, scFv BoNT/E3, scFv BoNT/E4, scFv BoNT/E3, IgG
3E1 LC NB NB 0.70 NB ND
3E2 LC-HN 0.62 1.16 0.15 0.16 0.002
3E3 LC NB NB 0.6 NB ND
3E4 LC-HN 4.7 >100 4.7 NB 0.70
3E5 LC 24.10 1.5 4.90 NB 1.4
3E6 HN 15.40 >100 15.4 >100 ND
3E6.1 HN 0.83 0.57 0.28 >10.0 0.04
3E6.2 HN 0.55 0.64 0.17 1.42 0.009
4E11 LC 12.67 12.39 14.20 NB ND
4E13 HC 4.38 NB 9.90 NB 7.24
4E16 LC 2.22 1.43 0.20 NB 0.15
4E17 HN 18.37 >100 14.09 >100 ND
4E17.1 HN 0.16 1.27 0.1 0.60 0.24
KD > 10 or 100 nM indicates that saturation was not achieved at a BoNT/E concentration of 10 nM or 100 nM,
respectively; NB = no observed binding at 100 nM BoNT/E. ND = not determined.
2.2. Epitope Mapping
The binding location of the different mAbs was determined using yeast display of five different
BoNT/E1 constructs comprising single or combined functional domains of BoNT/E1: LC-HN
(proteolytic and translocation domains), HN (translocation domain), HC (translocation plus binding
domain), HC (binding domain), and LC (light chain) as previously described for BoNT/A mAbs [37].
MAbs 3E6.1 (a higher affinity derivative of 3E6, see below) and 4E17.1 (a higher affinity derivative of
4E17) [35] bind to the HN domain, while 4E13 binds to the HC domain (Figure 1 and Table 1). MAb
3E2 binds the LC-HN, but did not bind either the HN or LC alone (Figure 1), indicating that this mAb
has a complex epitope spanning the LC and HN. MAbs 4E11 and 4E16 bind both the LC-HN and LC,
indicating that they bind LC epitopes.
For mAbs binding the same domain, epitope overlap was determined based on whether mAbs
could simultaneously bind BoNT/E. Competition for binding was determined by capturing BoNT/E
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by one of the yeast-displayed scFv followed by probing with each of the IgG (Table 2). The IgG binding
signal indicated whether epitopes overlapped. IgG did not bind BoNT/E when captured by the scFv
from which it was derived, as indicated by the low mean fluorescence intensity (MFI) signal (Table 2).
For the HN-binding mAbs 4E17.1 and 3E6/3E6.1, and the LC-HN-binding mAb 3E2, there was no
inhibition of binding of any of these mAbs by the other mAbs, indicating that each of these mAbs
bound non-overlapping epitopes (data not shown). Each of the other six LC mAbs showed overlap of
epitopes by one or more of the other LC mAbs as indicated by values shown in bold in Table 2 that
were less than 2.5-fold above control values. These studies allowed for the construction of an epitope
map showing the number of unique (non-overlapping) or overlapping epitopes recognized by the
BoNT/E mAbs (Figure 2). For the mAb pair 3E4/3E1, inhibition occurred in one direction (capture
with 3E1) but only showed a reduced signal compared to probing with other mAbs with capture in the
other direction (capture with 3E4.1). Thus, the 3E4 and 3E1 mAb footprints are shown as nearby but
not overlapping. As illustrated in Figure 2, 3E2 bound a unique epitope spanning LC and HN and was
not inhibited by any of the other mAbs.
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IgG with each expressed domain: light chain (LC), proteolytic and translocation domains (LC-HN), 
translocation domain (HN), translocation plus binding domain (HC), and binding domain (HC). All 
domains were well-displayed as indicated by a >2 log shift with anti-SV5-Alexa-647. All domains are 
bound only by domain-specific mAbs, with no binding of mAbs specific to other domains, 3E2 to LC-
HN, 3E6 and 4E17 to HN, 4E11 to LC, and 4E13 to HC. 
Figure 1. Toxin domain binding assays for five different botulinum type E neurotoxin (BoNT/E) mAbs.
Yeast-displayed BoNT/E1 domains were used as antigen to detect binding for each Alexa-labeled IgG.
Flow cytometry dot plots show binding results after the independ nt incubation of e ch IgG with each
expressed domain: light chain (LC), proteolytic and transloc tion dom ins (LC-HN), translocation
domain (HN), translocation plus binding domain (HC), and binding domain (HC). All domains were
well-displayed as indicated by a >2 log shift with anti-SV5-Alexa-647. All domains are bound only by
domain-specific mAbs, with no binding of mAbs specific to other domains, 3E2 to LC-HN, 3E6 and
4E17 to HN, 4E11 to LC, and 4E13 to HC.
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Table 2. Overlap of epitopes of BoNT/E-LC-binding mAbs. The ability of each of the mAbs binding
BoNT/E3 LC to inhibit the binding of other mAbs was determined by flow cytometry. Yeast-displayed
scFv were used to capture BoNT/E3 followed by incubation with one IgG and binding detection by
flow cytometry. Each mAb served as its own control based on the mean fluorescence intensity (MFI)
value for mAb binding to BoNT captured by the same mAb. Values in bold and underlined indicate that
mAb epitopes overlapped as defined by an MFI of less than 2.5-fold above the self-control background
MFI (italics). 3E4.1 is a higher affinity derivative of 3E4, which was used for these studies based on its
better ability to capture BoNT/E compared to 3E4.
Mean Fluorescence Intensity (MFI) of IgG Binding to Yeast scFv-Captured BoNT/E3
Capture mAb 3E1 3E2 3E3 3E4 3E5 3E6 4E11 4E13 4E16 4E17.1 No IgG
3E1 196 2916 283 134 6486 1558 5357 509 1919 3742 98
3E2 2492 276 5503 10,394 8503 6729 10,425 5843 11,564 6870 89
3E3 143 1255 252 138 1966 482 2712 188 681 646 105
3E4.1 509 17,993 359 236 12,747 14,858 301 11,952 10,433 3262 104
3E5 2059 6026 3175 3910 103 1455 100 1460 104 1429 103
3E6.1 6795 18,622 13,081 17,313 7654 230 9309 10,982 10,185 4270 105
4E11 844 4807 802 237 139 2346 241 2201 210 5708 95
4E13 739 3646 1141 1334 1306 1472 1176 238 1976 3602 99
4E16 2093 7133 5165 9466 232 4641 101 7109 163 4659 85
4E17.1 8975 9039 13,085 12,820 7247 14,713 9442 6911 9667 128 93
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BoNT/E [18]. MAb 3E2 binds an epitope with energetically important amino acid contributions from 
both the LC and HN at the interface where the LC packs against the HN (Figure 3). This result confirms 
that, in solution, BoNT/E has a globular structure rather than the extended structure seen for BoNT/A 
(PDB: 3BTA) [19] and B (PDB: 1EPW) [38]. MAb 3E6.1 binds the HN centered on alpha helix 20 at a 
site nearby that does not overlap with the epitope of 4E17.1 (Figure 3). Analysis of the binding of LC 
mAb 3E4, 4E16, 3E1, and 3E3 indicates that the LC epitope cluster is centered around amino acid 142 
and consists of three non-consecutive sequence segments, mainly the tips and loops of the first, 
second, sixth, and seventh beta strands and the second, third, and sixth alpha helices (Figure 3). The 
3E4 epitope was also identified to include amino acid side chains from the HN belt as it wraps around 
the LC. The epitopes of mAbs 4E17.1 and 4E13 have been previously reported. MAb 4E17.1 binds an 
epitope at the tip of the HN, near the 3E6.1 epitope (Figure 3) [33] MAb 4E13 binds an HC epitope 
Figure 2. Domain epitope map of BoNT/E mAbs. The BoNT/E domain bound by each mAb
was determined using yeast-displayed BoNT/E3 domains as described. Overlap of epitopes was
determined using a sandwich binding assay where BoNT/E3 was captured by a yeast-displayed scFv
and the ability of an individual IgG to bind BoNT/E was measured by flow cytometry (see Table 2).
One mAb (4E13) binds HC, two mAbs (4E17 and 3E6) bind non-overlapping HN epitopes, 3E2 binds
an epitope on both the LC and HN, 3E5, 4E11, 4E16, 3E1, and 3E4 bind LC and the belt portion of HN,
and 3E3 mAbs bind the L , with ea h mAb having an epitope that overlaps at l ast one other mAb.
Purple circle = binds HC; green circle = binds HN; red circle = binds epitope composed of HN and LC
amino acids; blue circles = binds LC.
Next, the fine epitopes of mAbs 3E1, 3E2, 3E4, 3E6.1, 4E16, 4E17.1, and 4E13 were determined by
creating libraries of domain mutants nd sele ting for loss of binding of one of he mAbs. Putative
epitopes were confirmed by introducing single alanine mutations into the mAb-specific domain and
measuring the impact on affinity [37]. Epitopes were mapped onto the X-ray crystal structure of
BoNT/E [18]. MAb 3E2 binds an epitope with energetically important amino acid contributions from
both the LC and HN at the interface where the LC packs against the HN (Figure 3). This result confirms
that, in solution, BoNT/E has a globular structure rather than the extended structure seen for BoNT/A
(PDB: 3BTA) [ 9] and B (PDB: 1EPW) [38]. MAb 3E6.1 binds the HN centered on alpha helix 20 at
a site nearby that does not overlap with the epitope of 4E17.1 (Figure 3). Analysis of the binding
of LC mAb 3E4, 4E16, 3E1, and 3E3 indicates that the LC epitope cluster is centered around amino
acid 142 and consists of three non-consecutive sequence segments, mainly the tips and loops of the
first, second, sixth, and seventh beta strands and the second, third, and sixth alpha helices (Figure 3).
The 3E4 epitope was also identified to include amino acid side chains from the HN belt as it wraps
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around the LC. The epitopes of mAbs 4E17.1 and 4E13 have been previously reported. MAb 4E17.1
binds an epitope at the tip of the HN, near the 3E6.1 epitope (Figure 3) [33] MAb 4E13 binds an HC
epitope consisting of amino acids R1100, R1101, K1102, S1179, Y1149, G1181, and F1184 [34]. MAb
4E13 interferes with the BoNT/E–SV2 interaction, thereby preventing binding and uptake of BoNT/E
into motor neurons [34]. The general location of the epitopes of mAbs 3E6.1, 4E16, and 4E17.1 has also
been confirmed by single particle electron microscopy [17].
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CDRH1 was chosen due to its small size (allowing for the capture of diversity in a relatively small 
library) and prior experience with diversifying this CDR in other affinity-maturation campaigns 
[33,36,40]. The affinity and cross-reactivity of 3E6.1 was further increased by diversifying five solvent-
Figure 3. Fine epitope map of BoNT/E mAbs. Space filling representation of BoNT/E crystal
structure [18], with the epitopes of mAbs 3E2, 3E6.1, 4E13, 4E16, and the LC epitope cluster and
4E17. Color-coding of the domains is: LC shown in yellow, HN in magenta, and HC in green.
2.3. Affinity Maturation of mAb 3E6
Effective BoNT neutralization requires high affinity binding (KD = 1 nM or less) of three mAbs at
non-overlapping epitopes that are conserved between BoNT subtypes [31]. MAbs 3E2 and 4E17.1 have
non-overlapping epitopes and bind subtypes BoNT/E1, E2, E3, and E4 with high affinity (Table 3).
MAb 3E6, however, has a relatively poor affinity for BoNT/E3 (1.0 × 10−8 M) and even poorer
affinity for BoNT/E2 and E4 (Table 1). To increase the affinity of 3E6, the light chain of 3E6 was
replaced with a repertoire of human light chains (chain shuffling) [33,39]. The chain-shuffled 3E6 scFv
repertoire was displayed on the surface of yeast to create a library of >106 transformants. Th resulting
yeast-displ yed scFv libraries were sequentiall s rt d on d creasing concentrations of BoNT/E3
until the diversity had collapsed to a few unique scFv. Individual colonies were sequenced and
characterized with respect to binding affinity to identify the scFv (3E6.1) with the highest affinity to
BoNT/E1, E2, E3, and E4 (Table 1). MAb 3E6.1 binds BoNT/E3 with a 55-fold (2.8 × 10−10 M) lower
KD as a yeast-displayed scFv compared to 3E6 (Table 1). The 3E6.1 IgG binds BoNT/E3 with high
affinity (KD = 3.9 × 10−11 M). The binding affinity to BoNT/E4 improved, with a KD of 9.7 × 10−8 M
(Table 3), but further improvements were desired.
Since the initial round of affinity maturati n i volved replacing the ntire light chain, the next
round of affinity maturation was focused on the heavy chain variable region, specifically CDRH1.
CDRH1 was chosen due to its small size (allowing for the capture of diversity in a relatively
small library) and prior experience with diversifying this CDR in other affinity-maturation
campaigns [33,36,40]. The affinity and cross-reactivity of 3E6.1 was further increased by diversifying
five solvent-accessible amino acids (TFSSY) in the VH antigen-binding loop H1 (CDRH1) as we have
previously described for affinity maturation of a BoNT/A mAb [36]. The resulting yeast-displayed
scFv libraries were sequentially sorted on decreasing concentrations of BoNT/E3 until the diversity
had collapsed to a few unique scFv. Individual colonies were sequenced and characterized with respect
to binding affinity in order to identify the highest affinity s Fv (mAb 3E6.2) to BoNT/E3. MAb 3E6.2
binds BoNT/E4 with a yeast-displaye scFv KD = 1.4 × 10−9 M, at least 7-fold higher than the 3E6.1
scFv. The 3E6.2 IgG binds all four BoNT/E subtypes with high affinity. The KD of 3E6.2 for BoNT/E4
is 5.4 × 10−10 M, 18-fold higher affinity than 3E6.1 (Table 3).
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Table 3. Binding affinity and kinetics of BoNT/E IgG for different BoNT/E subtypes. KD and
association rate constants for IgGs binding to different toxin subtypes determined using flow
fluorimetry in KinExA. The dissociation rate constant (koff) is calculated from the KD and kon.
mAb
KD (×10−12 M) kon (106 M−1 s−1) koff (10−6 s−1)
BoNT/E1 BoNT/E2 BoNT/E3 BoNT/E4 BoNT/E3 BoNT/E3
3E2 11.52 15.34 2.28 17.53 1.080 2.461
3E6.1 35.11 50.93 40.32 9720 0.5272 21.26
3E6.2 6.41 7.07 8.55 542 2.136 18.27
4E16 312.13 383.12 153.64 NB 0.4444 68.28
4E17.1 730.30 204.74 239.58 492.04 0.7968 190.90
2.4. Mouse Neutralization Assays
The potency of single mAbs, mAb pairs, and a combination of three mAbs was evaluated
using a standard mouse neutralization assay where BoNT/E and mAbs are pre-mixed and injected
intraperitoneally into mice [41]. Animals were monitored periodically and survival was determined
after five days. Mice receiving 50 µg of the single mAbs 3E6.1, 4E13, 4E16, and 4E17.1 showed a
prolonged time to death when challenged with 100 mouse LD50 of BoNT/E3; however, only one to
two mice out of ten survived (Figure 4). The most protective single mAb, 3E2, showed 100% survival
against 200 LD50 BoNT/E3 with an ED50 of approximately 500 LD50 (Figure 4). MAb pairs were
significantly more potent than single mAbs. Fifty µg of an equimolar mixture of 3E6.1 and 4E17.1
completely protected mice challenged with 1000 LD50 BoNT/E3, which was greater than ten times
more potent than either of the mAbs alone. The combination of 3E2 plus either 3E6.1 or 4E17.1 showed
even greater potency, with 10/10 mice surviving challenge with 20,000 LD50. This is about 40 times
more potent than 3E2 alone (Figure 4). The greatest potency is seen with a combination of three mAbs
binding non-overlapping epitopes. Ten of ten mice dosed with 5 µg of 3E2 + 3E6.1 + 4E17.1 survived
40,000 mouse LD50 BoNT/E3, which is approximately 20 times more potent than the best mAb pair
(Table 4). Similar high potency neutralization is seen for the mAb combination 3E2 + 3E6.1 + 4E16
(Table 4). Both of these mAb combinations neutralized BoNT/E1 with comparable potency to the
BoNT/E3 neutralization (Table 4). However, only the combination of 3E2 + 3E6.1 + 4E17.1 potently
neutralized BoNT/E4 (10/10 mice surviving challenge with 10,000 mouse LD50 plus 50 µg of mAb)
(Table 4). This is not surprising given that 4E16 does not bind BoNT/E4. As expected, the combination
of 3E2 + 3E6.2 + 4E17.1 was slightly more potent than the combination of 3E2 + 3E6.1 + 4E17.1 for
BoNT/E4 (Table 4). 3E6.2 binds BoNT/E4 with 7-fold higher affinity than 3E6.1.
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Figure 4. Ne tralization of BoNT/E3 by single bs and mAb p irs as det rm ed using the mouse
neutralization assay. Fifty µg of individual mAbs or an equimolar mixture of the mAb pairs (25 µg of
each mAb) was combined with the indicated amount of BoNT/E3 and injected intraperitoneally into
mice. The number of mice surviving at five days was determined.
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Table 4. Potency of combinations of three mAbs in the mouse neutralization assay. The indicated
amount of BoNT and an equimolar combination of the three mAbs at the dose indicated were injected
into cohorts of ten mice and the number of mice surviving was determined.
Number of Mice Surviving/10 Mice Treated
Antibody Dose 50 µg 10 µg 5 µg 2 µg
Antibody combination BoNT/E1: 40,000 LD50
3E2, 3E6.1, 4E16 9/10 9/10 9/10 0/10
3E2, 3E6.1, 4E17.1 10/10 10/10 0/10
BoNT/E3: 40,000 LD50
3E2, 3E6.1, 4E16 9/10 9/10 1/10
3E2, 3E6.1, 4E17.1 9/10 10/10 0/10
3E2, 3E6.2, 4E17.1 9/10 10/10 0/10
BoNT/E4: 40,000 LD50
3E2, 3E6.1, 4E16 0/10
BoNT/E4: 10,000 LD50
3E2, 3E6.1, 4E17.1 10/10 1/10
3E2, 3E6.2, 4E17.1 8/10 5/10
3. Discussion
Yeast display and sorting of scFv libraries constructed from the V-genes of humans immunized
with BoNT toxoid was used to isolate a panel of ten unique human mAbs to BoNT/E. Three of the ten
mAbs bound all four BoNT/E subtypes tested and two of these mAbs required affinity maturation in
order to achieve our target level binding to the four BoNT/E subtypes tested (E1, E2, E3, and E4) with a
KD less than 1.0× 10−9 M. In vivo BoNT/E3 neutralization by individual mAbs was relatively modest,
as expected, with mAb 3E2 showing the most potent neutralization having an ED50 of approximately
500 mouse LD50/50 µg of mAb. The other five individual mAbs tested showed minimal protection
against challenge with 100 mouse LD50 of BoNT/E3, including the mAb (4E13) previously shown
to bind to the BoNT/E–SV2 binding site and which blocked binding and uptake of BoNT/E into
motor neurons [34]. The mechanism underlying the more potent BoNT/E neutralization by mAb 3E2
compared to other mAbs is unclear; however, based on its high affinity and epitope straddling the HN
and LC, it could act by entering the neuron bound to BoNT and preventing or delaying intracellular
translocation [42] or by preventing HN dissociation from the LC-blocking substrate cleavage.
MAb combinations neutralized BoNT/E much more potently than individual mAbs, with 5.0 µg
total of a triple-antibody combination able to completely neutralize 40,000 LD50 of BoNT/E1 or
BoNT/E3 and 50 µg protecting against 10,000 LD50 BoNT/E4. While we did not formally titer the
potency of the three-mAb combination at a higher toxin concentration, these antibody combinations
could theoretically yield a neutralization capacity of 8 million mouse LD50/mg of mAb combination,
which would be the equivalent of 8000 International Units (IU)/mg. Where we have measured the
IU potency of a BoNT/A mAb combination, the value determined correlated closely with the value
calculated as just described [31].
The greatly increased potency observed for the triple mAb combinations may be due to several
different mechanisms. Binding of multiple mAbs could block several steps in the intoxication pathway,
for example, receptor binding and translocation [42,43]. Binding of multiple mAbs also results in an
avidity effect leading to an increase in mAb functional affinity [31]. It has also been shown that binding
of multiple mAbs leads to rapid Fc-mediated clearance via the liver [44]. In addition, the large size of
immune complexes likely slows the exit of BoNT from the circulation to its site of action.
Murine [45] camelid [46], macaque [47], and humanized macaque [47,48] mAbs neutralizing
BoNT/E have been reported by others. In the case of the murine mAbs, individual mAbs were also
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shown to be only weakly neutralizing, with 25 µg of mAb neutralizing at most 50 LD50 of BoNT/E.
Similar to the results reported here, 25 µg of a four or six mouse mAb combination synergized to
neutralize 20,000 to 40,000 mouse LD50 of BoNT/E [45]. Neutralization results have been reported
for individual camelid and humanized macaque mAbs (three mouse LD50 were neutralized by
150 mg/kg [46] and five mouse LD50 were neutralized by 2.5 ng of mAb [47], respectively); however,
the doses of BoNT studied are so much lower than those studied here that the comparability of potency
is unclear. This lack of comparability relates to the law of mass action; at a challenge dose of five LD50,
only 80% of BoNT needs to be neutralized for 50% survival while at a challenge dose of 100 LD50, 99%
of BoNT must be neutralized for 50% survival. In addition, the murine or macaque mAbs were only
evaluated for neutralization against a single subtype.
4. Conclusions
The BoNT/E mAb combination described here is highly potent, with a projected dose of 0.64 mg
to be equivalent to the 5100 IU of BAT in a single vial [27] (approximately 650 mg) used to treat human
botulism. Component mAbs were selected based on their ability to bind and neutralize four different
BoNT/E subtypes. Comparison of the fine mAb epitopes to the published sequence of the other
eight BoNT/E subtypes predicts that the mAbs would bind and neutralize them, though this was
not tested due to a lack of availability. Compared to equine BAT, which is immunogenic and has
reported hypersensitivity reactions including cardiac arrest and serum sickness, the BoNT/E mAbs
are human in sequence and should be significantly safer [27]. This work continues our efforts in
developing neutralizing recombinant antitoxins to all BoNT serotypes with the goal of replacing BAT
with a renewable, safer, more potent, and easier to administer recombinant antitoxin produced from
stable cell lines. The most advanced of these products is XOMA 3AB, a three-mAb combination of
human and humanized mAbs that has completed Phase 1 testing without serious adverse events (SAE)
and with mAb serum half-lives of 12–27 days [32]. A combination of three BoNT/B mAbs has also
completed Phase 1 testing in humans without SAE with pending pharmacokinetic data. The safety and
high potency of mAb combinations should allow for subcutaneous or intramuscular administration
compared to BAT, which must be diluted at least 10-fold into a volume of 200–500 mL and infused
slowly intravenously. This makes the mAb combination much easier to administer in a mass casualty or
exposure situation. Safety and a long serum half-life allows the mAb combinations to be administered
before symptoms appear or to be used as an alternative to a vaccine to provide multi-month immediate
immunity. The long serum half-life of two to three weeks compared to the 8–34 h half-life of BAT [27]
should also prevent the recurrence of botulism post treatment that has been reported for BAT [28].
Based on the results described here, an investigational new drug application (IND) has been filed for a
three-mAb combination for the treatment of botulism from type E BoNT (NTM-1633) that is expected
to enter clinical studies in 2018.
5. Materials and Methods
5.1. Ethics
The USAMRIID Institutional Animal Care and Use Committee approved the animal care and
use protocol to conduct the animal studies reported here. Research was conducted under an IACUC
approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes
and regulations relating to animals and experiments involving animals. The facility where this research
was conducted is accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care, International (AAALAC/I) and adheres to principles stated in the Guide for the Care
and Use of Laboratory Animals, National Research Council, 2011. The specific national regulations
and guidelines to which this animal care and use protocol adheres are the following: (1) 7 USC,
Sections 2131–2159, Chapter 54 “Animal Welfare Act”, and (CFR, Chapter 1, Subchapter A, Parts
1–4 “Animal Welfare Regulations”; (2) Health Research Extension Act of 1985, Public Law 99-158
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“Animals in Research” and the Public Health Service Policy in Humane Care and Use of Laboratory
Animals; (3) Biosafety in Microbiological and Biomedical Laboratories, 5th Edition, NIH, Human
and Health Services Publication (CDC) 21-112; (4) Army Regulation 40-33 “The Care and Use of
Animals in DOD Research, Development, Test and Evaluation or Training Programs”; and (5) DOD
Instruction 3216.01 “Use of Animals in DOD Programs”. DOD uses “The Guide for the Care and Use
of Laboratory Animals”, 8th Edition, Institute for Laboratory Animal Research, National Research
Council, as a guideline for the evaluation and accreditation of a program and it is based on the actual
national regulations and guidelines for animal care and use programs. The animals used in this study
were euthanized using carbon dioxide gas following the AVMA Guidelines on Euthanasia prior to
spleen removal.
The University of California, San Francisco (UCSF) Institutional Review Board approved the
human use protocol used for the studies described here. Human donors were laboratory workers
being immunized to work with BoNT who were recruited via an informational letter and who signed
an informed consent form.
5.2. Oligonucleotides for Library Construction
The primers for site-directed mutagenesis were designed and synthesized per the QuikChange
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) instructions. The primers
for human and mouse library construction were synthesized as described previously [35,49].
The spiked oligonucleotide for affinity maturation of 3E6.1 was as follows:
3E6.1mutH1rev GAC CCA GTG CAT AGC 521 542 542 511 532 GAA TCC AGA GGC TGC
where:
1 = 70% A + 10% T + 10% G + 10% C
2 = 70% T + 10% A + 10% G + 10% C
3 = 70% G + 10% T + 10% A + 10% C
4 = 70% C + 10% T + 10% G + 10% A
5 = 50% G + 50% C
PYDFor1: CCCCTCAACAACTAGCAAAGGCAGCCC
PYDRev: GGTGATGGTGATGATGACCGGTACGCGTAG
Link Rev: CGACCCGCCACCGCCAGAGCCACCTCCGCC
5.3. Strains, Media, Antibodies, and Toxin
YPD medium was used for growth of Saccharomyces cerevisiae strain EBY100, SD-CAA, for selection
of pYD2-transformed EBY100 and SG-CAA, and for induction of scFv expression on the surface of
EBY100. Escherichia coli strain DH5α was used for subcloning and preparation of plasmid DNA.
Pure holotoxin BoNT/E3 was purchased from Metabiologics (Madison, WI, USA). Crude extract
complex for subserotypes E2 and E4 was obtained from the U.S. Army Medical Research Institute of
Infectious Diseases (USAMRIID). Pure complex subserotype E1 was purchased (Wako chemicals USA
Inc., Richmond, VA, USA). All IgGs were expressed from Chinese hamster ovary (CHO) cells, while
the mouse anti-SV5 antibody was purified from hybridoma cells and labeled with an AlexaFluo-488 or
AlexaFluo-647 labeling kit (Invitrogen, Carlsbad, CA, USA). The secondary antibody, PE-conjugated
goat anti human-Fc, F(ab) was purchased (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA).
5.4. Yeast-Displayed Human scFv Library Construction and Library Sorting
To generate human mAbs that bind BoNT/E, total RNA was isolated from the blood of healthy
human donors immunized with investigational pentavalent BoNT toxoid (formalin-inactivated
BoNT/A, B, C, D, and E). cDNA synthesis, VH, and VK gene repertoire preparation and library
construction were performed as described previously [35]. The cDNA was synthesized by RT-PCR
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with oligo dT as the primer using a ThermoScript RT-PCR Kit (Invitrogen, Carlsbad, CA, USA). The VH
and Vk gene repertoires were amplified from cDNA by PCR with primers without gap tails and then
amplified with gap-tailed primers following gel purification as previously described [33,34]. VH and
Vk genes first were coupled with a (G4S)3 linker to obtain full-length scFv genes by splicing using
overlap extension PCR as previously described [35,36]. The scFv gene was inserted into the NcoI/Not
I restriction sites of the pYD2 plasmid and transformed into EBY100. The library size was determined
by plating a serially diluted transformation mixture on SD-CAA plates. To sort the libraries, scFv
display was induced by culturing in SG-CAA medium with 10% SD-CAA for at least 24 h. For sorting,
the libraries were incubated with 50 nM of BoNT/E3 labeled with Alexa-647 plus SV5 mAb labeled
with Alexa-488 at room temperature (RT) for 1 h. Subtype BoNT/E was used for initial sorting due
to its commercial availability as pure uncomplexed holotoxin. All subsequent washing and staining
steps were performed at 4 ◦C using ice-cold FACS buffer (phosphate-buffered saline, 0.5% bovine
serum albumin, pH 7.4). After washing, yeast clones were flow-sorted on a FACSAria II, and the
population with BoNT/E3-binding gated and collected. The collected yeast clones were cultured
and induced for the next round of sorting. After three rounds of sorting, the collected yeast clones
were plated on SD-CAA medium and cultured at 30 ◦C for 48 h. Individual colonies were picked,
grown, and induced in 96 deep-well plates. These colonies were then screened for binding using
the same staining conditions used for sorting. Unique BoNT/E3-binding clones were identified by
DNA sequencing. For isolation of additional BoNT/E specific scFv, the V-genes of scFv isolated
as described above (mAbs E1, E2, and E3) were converted to IgG, purified, and IgG labeled with
Alexa-647. The labeling described above was then modified by incubation with unlabeled BoNT/E3
(50 nM) followed by washing and then incubation with an Alexa-647-labeled IgG (2 µg/mL) plus
SV5-488. The use of labeled IgG versus labeled BoNT provided a much more robust staining and
sorting reagent.
5.5. Measurement of KD Values of Yeast-Displayed scFv
The KD values of yeast-displayed scFvs were measured by flow cytometry as previously described
with modification [36]. Briefly, 1 × 106 yeast-displaying scFv were incubated for 1 h at room
temperature in FACS buffer with six different concentrations of BoNT/E holotoxin, or complex,
that spanned the range 10-fold above and 10-fold below the expected KD. Ice-cold FACS buffer was
used to wash the samples, and 2 µg/mL each of an Alexa-647-labeled IgG that bound a different
epitope was added plus SV5-488 at 4 ◦C and incubated for 60 min. Finally, the yeast clones were
washed with ice-cold FACS buffer and the mean fluorescence intensity (MFl) of binding was measured
by flow cytometry as described previously [35,50].
5.6. Epitope Mapping
Epitopes were classified based on the ability of mAbs to compete with each other for binding
to BoNT/E as previously described [35,36]. Briefly, yeast-displayed scFv were incubated for 60 min
with 25 nM of BoNT/E3. The ability of other IgG to bind to BoNT/E3 captured by the yeast-displayed
scFv was detected by incubation for 60 min with 2 µg/mL of Alexa dye APC conjugated IgG and
1 µg/mL of Alexa-488-labeled SV5 antibody. Ability of the IgG to bind the scFv-captured BoNT/E was
determined by flow cytometry. The IgG that bound an overlapping epitope to yeast-displayed scFv
showed no APC signal, while those binding non-overlapping epitopes showed a positive APC signal.
5.7. Identification of mAb Domain and Fine Epitopes
To determine the BoNT/E domain bound by mAbs, synthetic genes were constructed for the
BoNT/E3 HC, HN, HC, LC, and LC-HN. The synthetic genes were cloned into the yeast-display
vector pYD2 as previously described [37] for BoNT/A domains to yield yeast-displayed HC, HN, HC,
LC, and LC-HN domains. Domain display was induced and individual IgG tested for binding by
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incubating yeast-displayed domains with 2 µg/mL IgG for 60 min at room temperature followed by
incubation with 1 µg/mL of Alexa-647-labeled anti-human Fc.
To determine the fine epitopes of BoNT/E mAbs, libraries of BoNT/E3 domains LC-HN, HN,
and HC were prepared by introducing random mutations into the domain gene using error-prone
PCR with the primers pYD-For/pYD-Rev and DNA polymerase Paq5000 (Agilent Tech, Palo Alto, CA,
USA) plus 12.5 µM MnCl2 as previously described [37]. The PCR product was gel-purified, ligated into
the NcoI/NotI restriction sites of the plasmid pYD2, and transformed into EBY100. The library was
cultured in SD-CAA medium for 48 h, and then 50 mL of the culture was induced in 500 mL SG-CAA
medium at 18 ◦C for 48 h. Amino acid residues critical for the binding of BoNT/E IgG were identified
by sorting for loss of IgG binding while maintaining binding of a control BoNT/E IgG binding a
non-overlapping epitope to the mAb being mapped exactly as previously described [37].
5.8. Site-Directed Mutagenesis
To confirm the energetically important amino acids on the BoNT/E domain critical for mAb
binding, single alanine mutants of BoNT/E domains in the putative fine epitope were prepared using
the QuikChange II-E Site-Directed Mutagenesis Kit (Agilent Tech, Palo Alto, CA, USA) following the
manufacturer’s instructions. Briefly, primers containing the mutation were used for PCR amplification
with the plasmid pYD2 containing the corresponding BoNT/E domain gene as a template for 18 cycles.
The PCR product was digested by DpnI to remove the parental methylated and hemi-methylated
DNA, which was then purified by StrataClean Resin and transformed into E. coli XL1-Blue. The alanine
mutants for each gene were then individually transformed into EBY100, grown in SD-CAA medium,
and induced for expression on the surface of EBY100. DNA sequencing was used to verify each
construct. The ∆∆G of binding for each alanine mutant was determined by comparing the IgG KD for
the alanine mutant domain to the wild-type KD as previously described [37].
5.9. Affinity Maturation Library Construction and Sorting
To increase the affinity of mAb 3E6, a VL chain-shuffled scFv library was created by PCR
amplifying the Vk gene repertoires from human immune scFv libraries using Pfu polymerase
(Stratagene) and the primers LinkFor and PYDRev. To further increase VL diversity, the VL repertoire
from a large non-immune scFv phage antibody library transferred from the phagemid vector pHEN1
and cloned into pYD2 was also used [51]. The 3E6 VH DNA was amplified from the scFv gene in pYD2
using a 5′ primer that annealed upstream of the VH gene (PYDFor1) and a 3′ primer that annealed in
the linker gene between the VH and VL genes (LinkRev). The gel-purified VH gene was mixed with
the gel-purified VL repertoires and combined with NcoI- and NotI-digested pYD2 vector DNA. This
mixture was used to transform LiAc-treated EBY100 cells by three-fragment gap repair. Library size
was measured as >107 transformants. To select higher affinity scFvs, the VL-shuffled library was sorted
as described above.
To create a library of CDRH1 mutants of the 3E6.1 scFv, a spiked oligonucleotide (3E6-H1Rev)
was used to introduce mutations into five amino acids located in the H1 loop of the 3E6.1 scFv as
previously described [40]. The oligonucleotide was designed to have a bias for a 25% or 50% wild-type
amino acid at each position, depending on codon usage. Library size was 5.6 × 107 transformants,
and selections and new scFv validation were done as described above.
5.10. Measurement of Solution Phase Affinity at Equilibrium
For selected IgGs, the solution phase affinity at equilibrium and binding kinetics were measured
using flow fluorimetry in a KinExA as previously described [36,50] except that BoNT/E toxins
were used.
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5.11. Measurement of In Vivo Toxin Neutralization
The mouse neutralization assay was performed as described previously [31]. Briefly, an equimolar
mixture of three IgG antibodies (0.5 to 50 µg total antibody) were premixed with a range of mouse
LD50 of BoNT/E1, /E3, or /E4 in a total volume of 0.5 mL of gelatin phosphate buffer and incubated at
room temperature for 30 min. The mixture was then injected intraperitoneally into cohorts of ten mice.
The animals were observed multiple times daily for clinical signs of botulism. Moribund animals were
euthanized. Surviving mice at the study endpoint were tabulated.
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